The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas [PDF]
Frontiers in Endocrinology, 2019 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size.
Xiaoshuang Liu +6 more
doaj +3 more sources
Dopamine Agonists for Pituitary Adenomas [PDF]
Frontiers in Endocrinology, 2018 Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing tumor size and hormonal secretion. Other pituitary tumor
Odelia Cooper, Yona Greenman
doaj +3 more sources
Metabolic effects of prolactin and the role of dopamine agonists: A review. [PDF]
Front Endocrinol (Lausanne), 2022 Prolactin is a polypeptide hormone that is well known for its role in reproductive physiology. Recent studies highlight its role in neurohormonal appetite regulation and metabolism. Elevated prolactin levels are widely associated with worsening metabolic
Kirsch P, Kunadia J, Shah S, Agrawal N.
europepmc +2 more sources
Dopamine agonists for preventing ovarian hyperstimulation syndrome. [PDF]
Cochrane Database Syst Rev, 2021 BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in assisted reproduction technology (ART).
Tang H +4 more
europepmc +2 more sources
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment [PDF]
Clinical Parkinsonism & Related Disorders, 2023 Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor ...
Stuart H. Isaacson +4 more
doaj +2 more sources
Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors [PDF]
Parkinson's Disease, 2021 Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016.
Caroline D. Binde +2 more
doaj +2 more sources
Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa? [PDF]
Frontiers in Nutrition, 2014 Anorexia nervosa is a severe psychiatric disorder most commonly starting during the teenage-years and associated with food refusal and low body weight. Typically there is a loss of menses, intense fear of gaining weight, and an often delusional quality ...
Guido Frank
openalex +2 more sources
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. [PDF]
Eur J Clin Pharmacol, 2020 To investigate the comparative effectiveness of dopamine agonists and monoamine oxidase type-B (MAO-B) inhibitors available for treatment of Parkinson’s disease.
Binde CD +4 more
europepmc +2 more sources
Experience with Dopamine Agonists in the Treatment of Prolactinomas [PDF]
Acta Medica Lituanica, 2022 The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of ...
Nadiya Barabash, Tetiana M. Tykhonova
doaj +2 more sources
Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists [PDF]
Clinical Parkinsonism & Related Disorders, 2021 Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral.
Mohammad Edrees Mohammad +6 more
doaj +2 more sources